Azurity Pharmaceuticals recently issued a recall for its ADHD and narcolepsy medication, Zenzedi. The recall was prompted by the discovery of a packaging error in a specific lot of Zenzedi 30 milligram tablets, where a pharmacist found carbinoxamine maleate, an antihistamine, instead of the intended dextroamphetamine sulfate – the active compound in Zenzedi.
This incident further complicates the ongoing national shortage of ADHD drugs since October 2022, making it even more challenging for individuals with ADHD to access their necessary medications.
Zenzedi is designed to treat ADHD and narcolepsy, containing dextroamphetamine sulfate, a stimulant. However, the mislabeled bottles contained carbinoxamine maleate, an allergy drug with sedative properties, posing potential risks for consumers. It’s crucial to note that carbinoxamine maleate has the opposite effect of a stimulant, as highlighted by the Mayo Clinic.
Individuals who inadvertently take carbinoxamine instead of Zenzedi may face an elevated risk of accidents or injuries. Potential side effects include drowsiness, increased eye pressure, urinary obstruction, and thyroid disorder, as indicated in the recall notice.
The specific recalled lot is identifiable by the lot number F230169A and an expiration date of June 2025. Fortunately, Azurity has not received any reports of serious injuries resulting from the medication mix-up.
Consumers with the recalled medication are advised to promptly return it to their pharmacy and contact their healthcare provider if they experience any adverse reactions. This recall emphasizes the need for heightened vigilance, particularly amid the existing shortage of ADHD medications, to ensure the safety and well-being of those relying on these essential drugs.
